




RealRate

PHARMACEUTICAL 2020

Arcturus Therapeutics Holdings Inc. Rank 226 of 358





RealRate

PHARMACEUTICAL 2020

Arcturus Therapeutics Holdings Inc. Rank 226 of 358



The relative strengths and weaknesses of Arcturus Therapeutics Holdings Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Arcturus Therapeutics Holdings Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 29% points. The greatest weakness of Arcturus Therapeutics Holdings Inc. is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 34% points.

The company's Economic Capital Ratio, given in the ranking table, is 27%, being 9.8% points below the market average of 36%.

Input Variable	Value in 1000 USD
Assets, Current	74,290
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	21,324
Liabilities, Non-Current	19,845
Other Assets	5,504
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	15,182
Other Net Income	-478
Other Revenues	20,789
Property and Equipment	2,349
Research and Development	33,640
Selling, General and Administrative Expense	12,662

Output Variable	Value in 1000 USD
Assets	82,143
Liabilities	56,351
Expenses	46,302
Revenues	20,789
Stockholders Equity	25,792
Net Income	-25,991
Comprehensive Net Income	-25,991
Economic Capital Ratio	27%